Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	149.42M
Revenue (ttm)	64.46M
Net Income (ttm)	-96.42M
Shares Out	21.38M
EPS (ttm)	-4.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,796
Open	7.10
Previous Close	7.12
Day's Range	6.95 - 7.19
52-Week Range	4.09 - 13.50
Beta	0.88
Analysts	Buy
Price Target	18.40 (+163.23%)
Earnings Date	Aug 15, 2025

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA
• Website: https://www.enanta.com

Financial Performance

In 2024, Enanta Pharmaceuticals's revenue was $67.64 million, a decrease of -14.61% compared to the previous year's $79.20 million. Losses were -$116.05 million, -13.28% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price target is $18.4, which is an increase of 163.23% from the latest price.

Price Target

$18.4

(163.23% upside)

Analyst Consensus: Buy